ABBOTT LABORATORIES (ABL.DE) Stock Price & Overview
FRA:ABL • US0028241000
Current stock price
The current stock price of ABL.DE is 91.17 EUR. Today ABL.DE is down by -0.31%. In the past month the price decreased by -7.64%. In the past year, price decreased by -24.81%.
ABL.DE Key Statistics
- Market Cap
- 158.423B
- P/E
- 20.44
- Fwd P/E
- 18.31
- EPS (TTM)
- 4.46
- Dividend Yield
- 2.41%
ABL.DE Stock Performance
ABL.DE Stock Chart
ABL.DE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ABL.DE. When comparing the yearly performance of all stocks, ABL.DE is a bad performer in the overall market: 88.6% of all stocks are doing better.
ABL.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ABL.DE. ABL.DE has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
ABL.DE Earnings
On January 22, 2026 ABL.DE reported an EPS of 1.5 and a revenue of 11.46B. The company missed EPS expectations (-0.75% surprise) and missed revenue expectations (-3.88% surprise).
ABL.DE Forecast & Estimates
35 analysts have analysed ABL.DE and the average price target is 114.26 EUR. This implies a price increase of 25.32% is expected in the next year compared to the current price of 91.17.
For the next year, analysts expect an EPS growth of 11.53% and a revenue growth 6.97% for ABL.DE
ABL.DE Groups
Sector & Classification
ABL.DE Financial Highlights
Over the last trailing twelve months ABL.DE reported a non-GAAP Earnings per Share(EPS) of 4.46. The EPS increased by 10.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.72% | ||
| ROA | 7.52% | ||
| ROE | 12.51% | ||
| Debt/Equity | 0.19 |
ABL.DE Ownership
ABL.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 2M6 | MEDTRONIC PLC | 14.21 | 98.371B | ||
| SHL | SIEMENS HEALTHINEERS AG | 13.71 | 40.969B | ||
| PHIA | KONINKLIJKE PHILIPS NV | 15.35 | 22.841B | ||
| PHI1 | KONINKLIJKE PHILIPS NV | 15.33 | 22.812B | ||
| BIM | BIOMERIEUX | 18.34 | 10.611B | ||
| OBCK | OTTOBOCK SE & CO KGAA | 17.55 | 3.436B | ||
| DIA | DIASORIN SPA | 14.23 | 3.313B | ||
| AFX | CARL ZEISS MEDITEC AG - BR | 11.84 | 2.236B | ||
| DRW3 | DRAEGERWERK AG - PREF | 11.37 | 1.75B | ||
| DRW8 | DRAEGERWERK AG | 8.67 | 1.351B | ||
| ELN | EL.EN. SPA | 15.69 | 979.832M | ||
| EUZ | ECKERT & ZIEGLER SE | 17.38 | 957.246M | ||
| GVS | GVS SPA | 12.2 | 691.453M |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About ABL.DE
Company Profile
Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. The company is headquartered in Abbott Park, Illinois and currently employs 115,000 full-time employees. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. The company serves people in more than 160 countries.
Company Info
IPO: 1937-03-01
ABBOTT LABORATORIES
100 Abbott Park Road, Abbot Park
ABBOTT PARK ILLINOIS US
Employees: 115000
Phone: 12246676100
ABBOTT LABORATORIES / ABL.DE FAQ
What does ABL do?
Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. The company is headquartered in Abbott Park, Illinois and currently employs 115,000 full-time employees. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. The company serves people in more than 160 countries.
Can you provide the latest stock price for ABBOTT LABORATORIES?
The current stock price of ABL.DE is 91.17 EUR. The price decreased by -0.31% in the last trading session.
Does ABL stock pay dividends?
ABBOTT LABORATORIES (ABL.DE) has a dividend yield of 2.41%. The yearly dividend amount is currently 2.06.
What is the ChartMill rating of ABBOTT LABORATORIES stock?
ABL.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
How is the market expecting ABL stock to perform?
35 analysts have analysed ABL.DE and the average price target is 114.26 EUR. This implies a price increase of 25.32% is expected in the next year compared to the current price of 91.17.
What is the expected growth for ABL stock?
The Revenue of ABBOTT LABORATORIES (ABL.DE) is expected to grow by 6.97% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.